**Descovy**
(tenofovir alafenamide and emtricitabine)

Effective Date 01/24/2017
Developed 12/01/2016 by R. Sterling, MD
Date Approved by P&T Committee: 1/24/17, 1/23/18, 1/22/19, 2/18/20

**DESCOVY** is a fixed dose combination tablet containing emtricitabine (FTC) 200 mg and tenofovir alafenamide (TAF) 25 mg. FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted *in vivo* to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate.

Note:
VCHCP requires that Combivir be prescribed by an Immunology Clinic physician with current American Academy of HIV Medicine (AAHIVM) certification or a physician boarded in Infectious Disease.

**Pre-authorization Criteria:** HIV-1 infection (in combination with other antiretroviral agents) in adults and pediatric patients 12 years of age and older
NOTE: not indicated for post-exposure prophylaxis; not approved for chronic hepatitis B infection

**Dosing:** one tablet daily, with or without food

**Dosage Forms:** combination tablet emtricitabine 200 mg and tenofovir alafenamide 25 mg

**Adverse Reactions/Precautions:** Black Box Warnings: may exacerbate hepatitis B infection in HIV patients; fatal lactic acidosis with steatosis has been reported; nausea and vomiting; decreased bone mineral density; immune reconstitution syndrome (reactivation of inflammatory response to latent infection); renal toxicity (caution using NSAIDs);

**Drug Interactions:** use caution with NSAIDs (renal toxicity); may increase serum concentration: acyclovir, valacyclovir; may decrease serum concentration: phenytoin, fosphenytoin, carbamazepine, phenobarbital, rifampin
REFERENCES:

Descovy (emtricitabine and tenofovir alafenamide) [prescribing information]. Foster City, CA: Gilead Sciences; April 2016.

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors

Revision History:
Date Developed: 12/01/16 by R. Sterling, MD
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>